Skip to main content

International Journal of Clinical Oncology

Ausgabe 4/2024

Inhalt (13 Artikel)

Special Article

Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022

Eiki Ichihara, Nobuaki Ochi, Go Makimoto, Kenichiro Kudo, Daijiro Harada, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Toshio Kubo

Cancer Statistics

Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021

Hidekatsu Nakai, Takahiro Higashi, Tamaki Kakuwa, Noriomi Matsumura

Original Article

Analgesic efficacy and safety of percutaneous thermal ablation plus cementoplasty for painful bone metastases: a systematic review and meta-analysis

Tomohiro Matsumoto, Rika Yoshimatsu, Marina Osaki, Junki Shibata, Hitomi Maeda, Kana Miyatake, Yoshinori Noda, Tomoaki Yamanishi, Takuji Yamagami

Open Access Original Article

Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study

Yuki Katsuya, Tatsuya Yoshida, Atsuo Takashima, Kan Yonemori, Akihiro Ohba, Shu Yazaki, Shigehiro Yagishita, Hiroko Nakahama, Osamu Kobayashi, Masatoshi Yanagida, Yasuhiro Irino, Akinobu Hamada, Noboru Yamamoto

Original Article

Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study

Shigeki Kataoka, Yoshitaka Nishikawa, Taro Funakoshi, Takahiro Horimatsu, Minoru Sakuragi, Eiichiro Uchino, Shusuke Hiragi, Shinya Yamamoto, Kaoru Sakai, Takeshi Matsubara, Motoko Yanagita, Manabu Muto

Open Access Original Article

Association of D-dimer level with thrombotic events, bleeding, and mortality in Japanese patients with solid tumors: a Cancer-VTE Registry subanalysis

Mashio Nakamura, Masato Sakon, Mitsuru Sasako, Takuji Okusaka, Hirofumi Mukai, Keiichi Fujiwara, Hideo Kunitoh, Mari S. Oba, Hideo Wada, Jun Hosokawa, Atsushi Takita, Masataka Ikeda

Open Access Original Article

Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance

Sena Yamamoto, Chiharu Kondoh, Hideko Nakagoshi, Mayuko Kakumen, Kana Yasuhara, Mayumi Nakai, Naoko Kodani, Kazumi Sunda, Chizuru Higashide, Megumi Katayama, Harue Arao

Open Access Original Article

Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan

Junji Furuse, Fumihiko Osugi, Koji Machii, Koji Niibe, Toshimitsu Endo

Original Article

Hydronephrosis severity as a predictor of postoperative renal function decline following laparoscopic radical nephroureterectomy

Toru Kanno, Go Kobori, Ryoichi Saito, Katsuhiro Ito, Hiromichi Nakagawa, Toshifumi Takahashi, Shigeki Koterazawa, Naoto Takaoka, Shinya Somiya, Takao Haitani, Kanji Nagahama, Masaaki Ito, Yoshihito Higashi, Seiji Moroi, Toshiya Akao, Hitoshi Yamada

Original Article

First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data

Hiroki Ishihara, Kenji Omae, Yuki Nemoto, Ryo Ishiyama, Hidekazu Tachibana, Koichi Nishimura, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi

Open Access Original Article

Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy

Honami Sato, Takahiro Kobayashi, Yoshihiro Kameoka, Kazuaki Teshima, Atsushi Watanabe, Masahiro Yamada, Takaya Yamashita, Shinsuke Noguchi, Yoshihiro Michisita, Naohito Fujishima, Jun Kuroki, Naoto Takahashi

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.